Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining the report for the test Combined Screening- AutoDELFIA (Astraia) is 7 days.

What are the prerequisites for the test Combined Screening- AutoDELFIA (Astraia)

  • Maternal age between 11 and 48 years old
  • Singleton pregnancy
  • Gestational age between 10 weeks 0 days and 13 weeks 6 days
  • Fetal crown-rump length between 45mm and 84mm
  • Availability of maternal weight, height and smoking status
  • Availability of fetal heart rate

What are the measure values for the test Combined Screening- AutoDELFIA (Astraia)

  • Alpha-fetoprotein (AFP) - ng/mL
  • Free Beta human chorionic gonadotropin (Free Beta-hCG) - mIU/mL
  • Unconjugated Estriol (uE3) - ng/mL
  • Pregnancy-associated plasma protein-A (PAPP-A) - mIU/mL

What does this test Combined Screening- AutoDELFIA (Astraia) identify?

Combined Screening- AutoDELFIA (Astraia)

The Combined Screening- AutoDELFIA test is used to identify the risk of certain chromosomal abnormalities in a developing fetus. This test combines the results of two different screening tests: the first trimester screening test and the second trimester maternal serum screening test.

  • First Trimester Screening Test: This test measures the levels of two hormones in the mother's blood (PAPP-A and free beta-hCG) and combines this with an ultrasound measurement of the thickness of the nuchal translucency (a pocket of fluid at the back of the fetus's neck). Abnormal levels of these hormones or an increased nuchal translucency measurement may indicate a higher risk of chromosomal abnormalities such as Down syndrome.
  • Second Trimester Maternal Serum Screening Test: This test measures the levels of certain proteins in the mother's blood (AFP, hCG, uE3, and Inhibin-A). Abnormal levels of these proteins may also indicate a higher risk of chromosomal abnormalities.

By combining the results of these two screening tests, the Combined Screening- AutoDELFIA test provides a more comprehensive assessment of the risk of chromosomal abnormalities in the fetus, allowing healthcare providers to offer further diagnostic testing or counseling to parents as needed.

Why is this test Combined Screening- AutoDELFIA (Astraia) taken?

Combined Screening- AutoDELFIA (Astraia)

The Combined Screening test is taken to assess the risk of certain chromosomal abnormalities in a developing fetus. This test combines two methods - AutoDELFIA and Astraia - to provide a comprehensive evaluation of the fetus's health.

The AutoDELFIA method measures the levels of certain hormones in the mother's blood, such as PAPP-A (Pregnancy-associated plasma protein-A) and hCG (Human chorionic gonadotropin). Abnormal levels of these hormones can indicate a higher risk of chromosomal abnormalities, such as Down syndrome.

The Astraia method uses ultrasound measurements, such as nuchal translucency (the thickness of the fluid-filled space at the back of the fetus's neck), to further assess the risk of chromosomal abnormalities. Combining the results from both methods can provide a more accurate assessment of the fetus's health.

Overall, the Combined Screening test is taken to help expectant parents make informed decisions about their pregnancy and to potentially identify any potential health concerns early on.

No FAQs available.

Customer Google Rating